Balaxi Pharmaceuticals Limited production unit, located at a Pharma SEZ near Hyderabad will commence by March 2024, focusing on General Oral Solid Dosage (OSD) and Liquid Injection formulations markets in Latin America.

This will drive backward integration of the supply chain to these countries, currently outsourced through contract manufacturing relationships. This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit margins. From the operations standpoint, Balaxi will establish a manufacturing ecosystem that affords better control, improves regulatory processes and reduces time to market for new product launches. Over the medium term, Balaxi sees several new market opportunities opening up for its product lines.

As a part of its corporate evolution – from a player currently participating in semi-regulated markets to gradually entering new global markets – Balaxi Pharmaceuticals Limited is moving its business model from ‘Asset Light’ to ‘Asset Right’. The company is setting up an EU GMP compliant pharmaceutical manufacturing unit for which it has acquired land in a Pharma SEZ located at Jadcherla, Hyderabad.

"We are also taking forward our manufacturing initiative that will allow us to create strong backward integration in our supply chain, completely reliant on outsourcing at present. Production from our planned facility will find immediate traction from established demand in existing markets. This EU GMP- compliant unit is also expected to open up new markets for our products, resulting in shorter pay-back on the investment and strong return on capital," said Ashish Maheshwari, Chairman & Managing Director, Balaxi Pharmaceuticals Limited.